Skip to content
Sign in

BRTX · NASDAQ

BioRestorative Therapies (BRTX) Stock Price & Fundamentals

$1,284.72+0.64%+$8.12End-of-day price as of Oct 9, 2026

BioRestorative Therapies (BRTX) closed at $1,284.72 on Oct 9, 2026, up 0.64% from the previous close of $1,276.60.

Share price, past year

1Y +20.79%

52-week range $1,033.80 – $1,392.45. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$1,284.72
Sep 30, 2026$1,295.91
Aug 31, 2026$1,370.27
Jul 31, 2026$1,350.69
Jun 30, 2026$1,295.08
May 29, 2026$1,249.52
Apr 30, 2026$1,286.34
Mar 31, 2026$1,146.93
Feb 27, 2026$1,119.98
Jan 30, 2026$1,093.64
Dec 31, 2025$1,055.15
Nov 28, 2025$1,041.87
Oct 31, 2025$1,064.69

Key statistics

Market cap
$32.73B
P/E (TTM)
—
EPS (TTM)
−$1.06
Revenue (TTM)
$357.87K
Net income (TTM)
−$11.06M
Shares outstanding
25.5M
Dividend yield
—
52-week range
$1,033.80 – $1,392.45

BioRestorative Therapies's market cap is $32.73B, based on a share price of $1,284.72 and 25.5M shares outstanding as of Mar 31, 2026.

Financials

BioRestorative Therapies reported revenue of $359.70K for fiscal 2025, down 10.30% from fiscal 2024.

BioRestorative Therapies reported a net loss of $14.24M in fiscal 2025.

Annual revenue

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
BioRestorative Therapies annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$359.70K−10.3%−$14.24M−3,959.4%−$1.58−$10.91M
FY2024ended Dec 31, 2024$401.00K+175.0%−$8.98M−2,239.3%−$1.16−$8.34M
FY2023ended Dec 31, 2023$145.80K+21.7%−$10.42M−7,145.2%−$2.47−$6.60M
FY2022ended Dec 31, 2022$119.80K+160.4%−$13.22M−11,037.0%−$3.65−$6.18M
FY2021ended Dec 31, 2021$46.00K−40.3%−$44.30M−96,311.5%−$37.30−$3.36M
FY2020ended Dec 31, 2020$77.00K−40.8%−$11.27M−14,639.9%−$28.56—
FY2019ended Dec 31, 2019$130.00K+17.1%−$14.65M−11,267.6%−$0.66−$6.95M
FY2018ended Dec 31, 2018$111.00K+37.0%−$12.52M−11,277.3%−$1.64−$5.12M
FY2017ended Dec 31, 2017$81.00K+122.8%−$9.44M−11,660.1%−$1.74−$3.86M
FY2016ended Dec 31, 2016$36.36K—−$8.64M−23,755.4%−$2.10—
BioRestorative Therapies quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q1 FY2026ended Mar 31, 2026$23.17K−$2.15M−$0.12
Q4 FY2025ended Dec 31, 2025$19.60K−$3.21M−$0.31
Q3 FY2025ended Sep 30, 2025$11.80K−$3.04M−$0.33
Q2 FY2025ended Jun 30, 2025$303.30K−$2.66M−$0.30
Q1 FY2025ended Mar 31, 2025$25.00K−$5.34M−$0.64
Q4 FY2024ended Dec 31, 2024$43.30K−$1.64M−$0.20
Q3 FY2024ended Sep 30, 2024$233.60K−$1.09M−$0.13
Q2 FY2024ended Jun 30, 2024$89.10K−$4.03M−$0.50

Company profile

Name
BioRestorative Therapies, Inc.
Ticker
BRTX
Exchange
NASDAQ
Industry (SEC SIC)
Services-Misc Health & Allied Services, NEC
Headquarters
40 Marcus Drive, Suite One, Melville, NY
Incorporated in
NV
Fiscal year ends
December
SEC CIK
0001505497

Recent SEC filings

Frequently asked questions

What is BioRestorative Therapies's stock price?

BioRestorative Therapies (BRTX) closed at $1,284.72 on Oct 9, 2026, up 0.64% from the previous close of $1,276.60.

What is BioRestorative Therapies's market cap?

BioRestorative Therapies's market cap is $32.73B, based on a share price of $1,284.72 and 25.5M shares outstanding as of Mar 31, 2026.

How much revenue does BioRestorative Therapies make?

BioRestorative Therapies reported revenue of $359.70K for fiscal 2025, down 10.30% from fiscal 2024.

Does BioRestorative Therapies pay a dividend?

BioRestorative Therapies's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from BioRestorative Therapies, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures